Low-dose radiation plus immunotherapy and chemo before gastric cancer surgery
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new combination of low-dose radiation, an immunotherapy drug (tirelizumab), and chemotherapy (SOX) given before surgery for locally advanced gastric or gastroesophageal junction cancer. The goal is to see if this approach can shrink tumors more effectively.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with adenocarcinoma of the stomach or where the stomach meets the esophagus (confirmed by biopsy).
- Your cancer is stage cT4N+M0, meaning it has spread to nearby lymph nodes but not to distant organs.
- You are between 18 and 75 years old.
- You have not had any prior cancer treatment like chemotherapy, radiation, or immunotherapy.
- Your overall health is good (ECOG score 0 or 1), and your blood counts and organ function meet specific levels.
- You do not have active autoimmune disease, serious infections, or a history of stomach surgery for cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests combining chemotherapy (SOX), an immunotherapy drug (tislelizumab), and low-dose radiation before surgery for people with locally advanced stomach or gastroesophageal junction cancer. The goal is to see if this combination shrinks tumors more effectively.
This trial tests a combination of low-dose radiotherapy, chemotherapy, and an immunotherapy drug (tislelizumab) before and after surgery for locally advanced stomach or gastroesophageal junction cancer. The goal is to see if this approach can improve outcomes compared to standard treatment.
This trial tests a combination of low-dose radiation, chemotherapy, and an immunotherapy drug (AK112) for people with advanced stomach or gastroesophageal junction cancer that has progressed after first-line treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests a new immunotherapy drug (serplulimab) combined with standard chemotherapy before surgery for patients with locally advanced stomach or gastroesophageal junction cancer. The goal is to see if this combination helps shrink the tumor and improve outcomes.
This trial studies giving immunotherapy together with chemotherapy and radiation before surgery for esophagogastric junction cancer. It aims to shrink the tumor and improve outcomes for people with early locally advanced, HER2-negative disease.
This trial tests a combination of chemotherapy (FLOT), an immunotherapy drug (pembrolizumab), and short-course radiation before surgery for gastroesophageal junction cancer. The goal is to see if this approach improves outcomes.
Hear when a new Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.